Warts - Pipeline Review, H1 2016

Published: Feb, 2016 | Pages: 99 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Warts - Pipeline Review, H1 2016

Summary


Global Markets Direct's, 'Warts - Pipeline Review, H1 2016', provides an overview of the Warts pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Warts, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Warts and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


Scope

- The report provides a snapshot of the global therapeutic landscape of Warts
- The report reviews pipeline therapeutics for Warts by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Warts therapeutics and enlists all their major and minor projects
- The report assesses Warts therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Warts

Reasons to buy


- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Warts
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Warts pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Warts Overview 9
Therapeutics Development 10
Pipeline Products for Warts - Overview 10
Warts - Therapeutics under Development by Companies 11
Warts - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Warts - Products under Development by Companies 16
Warts - Companies Involved in Therapeutics Development 18
3M Drug Delivery Systems 18
Aclaris Therapeutics, Inc. 19
Agilvax, Inc. 20
Biogenomics Limited 21
BioMAS Ltd. 22
Biota Pharmaceuticals, Inc. 23
Foamix Pharmaceuticals Ltd. 24
G&E Herbal Biotechnology Co., Ltd. 25
Helix BioPharma Corp. 26
Laboratories Ojer Pharma S.L. 27
LEO Pharma A/S 28
MediGene AG 29
NanoViricides, Inc. 30
Nielsen Biosciences, Inc. 31
Novan, Inc. 32
Novartis AG 33
Promius Pharma, LLC 34
RXi Pharmaceuticals Corporation 35
Tamir Biotechnology, Inc. 36
Verrica Pharmaceuticals Inc. 37
Zydus Cadila Healthcare Limited 38
Warts - Therapeutics Assessment 39
Assessment by Monotherapy Products 39
Assessment by Combination Products 40
Assessment by Target 41
Assessment by Mechanism of Action 43
Assessment by Route of Administration 45
Assessment by Molecule Type 47
Drug Profiles 49
(cervical cancer + genital warts) vaccine - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
(digoxin + furosemide) - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
AS-101 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
AX-03 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
BTA-074 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Candida Albicans Antigen - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
DFD-05 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
diphencyprone - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Herpecide - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
human papillomavirus [serotypes 6, 11] (bivalent) vaccine - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
hydrogen peroxide - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
imiquimod - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
imiquimod SR - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
ingenol mebutate - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
interferon alfa-2b - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
interferon alpha-2b (recombinant) - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
LFX-453 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
povidone iodine - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
PP-210 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
ranpirnase - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
SB-204 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
SB-206 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
sinecatechins - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Small Molecule to Agonize TLR-7 and TLR-8 for Oncology, Allergic Rhinitis, Actinic Keratosis and Warts - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
SRT-100 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
VP-100 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Warts - Recent Pipeline Updates 84
Warts - Dormant Projects 92
Warts - Discontinued Products 93
Warts - Product Development Milestones 94
Featured News & Press Releases 94
Dec 21, 2015: RXi Pharmaceuticals Announces the Initiation of a Phase 2 Trial in Dermatology with Samcyprone for Cutaneous Warts 94
Dec 07, 2015: Aclaris Therapeutics Initiates Phase 2 Clinical Trial of A-101 for Treatment of Common Warts 94
Feb 20, 2015: Medigene receives positive decision on marketing authorisation for Veregen in 8 additional European countries 95
Sep 30, 2014: Veregen Marketing Authorization Process initiated for eight additional European countries 95
Jul 16, 2014: Paladin Labs Announces the Canadian Launch of Veregen 95
Jun 12, 2014: Medigene announces market launch of Veregen in Belgium, Denmark and Finland 96
Apr 08, 2014: Medigene and Kora Healthcare sign agreement for the commercialisation of Veregen® in United Kingdom and Ireland 96
Dec 18, 2013: Medigene's drug Veregen launched in Norway and Sweden 96
Dec 18, 2013: Medigene's drug Veregen launched in Norway and Sweden 97
Dec 11, 2013: Medigene announces Veregen to be launched in the Czech Republic, Poland, Hungary, and Slovakia 97
Appendix 98
Methodology 98
Coverage 98
Secondary Research 98
Primary Research 98
Expert Panel Validation 98
Contact Us 98
Disclaimer 99

List of Tables

Number of Products under Development for Warts, H1 2016 10
Number of Products under Development by Companies, H1 2016 11
Number of Products under Development by Companies, H1 2016 (Contd..1) 12
Comparative Analysis by Late Stage Development, H1 2016 13
Comparative Analysis by Clinical Stage Development, H1 2016 14
Comparative Analysis by Early Stage Development, H1 2016 15
Products under Development by Companies, H1 2016 16
Products under Development by Companies, H1 2016 (Contd..1) 17
Warts - Pipeline by 3M Drug Delivery Systems, H1 2016 18
Warts - Pipeline by Aclaris Therapeutics, Inc., H1 2016 19
Warts - Pipeline by Agilvax, Inc., H1 2016 20
Warts - Pipeline by Biogenomics Limited, H1 2016 21
Warts - Pipeline by BioMAS Ltd., H1 2016 22
Warts - Pipeline by Biota Pharmaceuticals, Inc., H1 2016 23
Warts - Pipeline by Foamix Pharmaceuticals Ltd., H1 2016 24
Warts - Pipeline by G&E Herbal Biotechnology Co., Ltd., H1 2016 25
Warts - Pipeline by Helix BioPharma Corp., H1 2016 26
Warts - Pipeline by Laboratories Ojer Pharma S.L., H1 2016 27
Warts - Pipeline by LEO Pharma A/S, H1 2016 28
Warts - Pipeline by MediGene AG, H1 2016 29
Warts - Pipeline by NanoViricides, Inc., H1 2016 30
Warts - Pipeline by Nielsen Biosciences, Inc., H1 2016 31
Warts - Pipeline by Novan, Inc., H1 2016 32
Warts - Pipeline by Novartis AG, H1 2016 33
Warts - Pipeline by Promius Pharma, LLC, H1 2016 34
Warts - Pipeline by RXi Pharmaceuticals Corporation, H1 2016 35
Warts - Pipeline by Tamir Biotechnology, Inc., H1 2016 36
Warts - Pipeline by Verrica Pharmaceuticals Inc., H1 2016 37
Warts - Pipeline by Zydus Cadila Healthcare Limited, H1 2016 38
Assessment by Monotherapy Products, H1 2016 39
Assessment by Combination Products, H1 2016 40
Number of Products by Stage and Target, H1 2016 42
Number of Products by Stage and Mechanism of Action, H1 2016 44
Number of Products by Stage and Route of Administration, H1 2016 46
Number of Products by Stage and Molecule Type, H1 2016 48
Warts Therapeutics - Recent Pipeline Updates, H1 2016 84
Warts - Dormant Projects, H1 2016 92
Warts - Discontinued Products, H1 2016 93